EP1589980A4 - DIAGNOSTIC AND TREATMENT METHODS FOR INTERSTITIAL PULMONARY DISEASES - Google Patents

DIAGNOSTIC AND TREATMENT METHODS FOR INTERSTITIAL PULMONARY DISEASES

Info

Publication number
EP1589980A4
EP1589980A4 EP03811670A EP03811670A EP1589980A4 EP 1589980 A4 EP1589980 A4 EP 1589980A4 EP 03811670 A EP03811670 A EP 03811670A EP 03811670 A EP03811670 A EP 03811670A EP 1589980 A4 EP1589980 A4 EP 1589980A4
Authority
EP
European Patent Office
Prior art keywords
diagnostic
treatment methods
pulmonary diseases
interstitial pulmonary
interstitial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03811670A
Other languages
German (de)
French (fr)
Other versions
EP1589980A2 (en
Inventor
Jeffrey A Whitsett
Stephan W Glasser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of EP1589980A2 publication Critical patent/EP1589980A2/en
Publication of EP1589980A4 publication Critical patent/EP1589980A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP03811670A 2002-12-09 2003-12-09 DIAGNOSTIC AND TREATMENT METHODS FOR INTERSTITIAL PULMONARY DISEASES Withdrawn EP1589980A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43194902P 2002-12-09 2002-12-09
US431949P 2002-12-09
PCT/US2003/038915 WO2004056310A2 (en) 2002-12-09 2003-12-09 Methods of diagnosis and treatment of interstitial lung disease

Publications (2)

Publication Number Publication Date
EP1589980A2 EP1589980A2 (en) 2005-11-02
EP1589980A4 true EP1589980A4 (en) 2007-04-04

Family

ID=32681947

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03811670A Withdrawn EP1589980A4 (en) 2002-12-09 2003-12-09 DIAGNOSTIC AND TREATMENT METHODS FOR INTERSTITIAL PULMONARY DISEASES

Country Status (7)

Country Link
EP (1) EP1589980A4 (en)
JP (1) JP2006519588A (en)
CN (1) CN100401896C (en)
AU (1) AU2003302740A1 (en)
BR (1) BR0317132A (en)
CA (1) CA2507613A1 (en)
WO (1) WO2004056310A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009183176A (en) * 2008-02-05 2009-08-20 Univ Of Tokyo IL-1 type II receptor gene deletion mutant mouse
CN102300582A (en) 2009-01-30 2011-12-28 阿尔法贝塔公司 Compounds and methods for treating Alzheimer's disease
WO2011162655A1 (en) 2010-06-24 2011-12-29 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
WO2012138284A1 (en) 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
WO2016044681A1 (en) * 2014-09-18 2016-03-24 North Carolina State University Mammalian lung spheroids and lung spheroid cells and uses thereof
CN111972354B (en) * 2019-05-24 2021-11-30 凯斯艾生物科技（苏州）有限公司 Method for constructing interstitial pneumonia model with autoimmune characteristics
CN111296364B (en) * 2019-10-27 2022-06-24 上海莱士血液制品股份有限公司 Gene modification method for mouse animal model and application thereof
US11895994B2 (en) 2019-10-27 2024-02-13 Shanghai Raas Blood Products Co., Ltd. Humanized knock-in mouse expressing human Protein C
AU2021251208A1 (en) * 2020-04-08 2022-11-10 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
CN115772539B (en) * 2022-11-17 2024-06-21 南京医科大学 A bilateral lung-deficient mouse model with type Ⅰ tracheal hypoplasia phenotype and its construction method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047623A1 (en) * 1999-02-12 2000-08-17 Chiesi Farmaceutici S.P.A. Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant
WO2000076535A1 (en) * 1999-06-11 2000-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
WO2001080633A2 (en) * 2000-04-26 2001-11-01 Children's Hospital Medical Center Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
US6458759B1 (en) * 1996-04-26 2002-10-01 Ony, Inc. Compositions and methods for isolating lung surfactant hydrophobic proteins SP-B and SP-C
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547864A (en) * 1993-01-13 1996-08-20 Ajinomoto Co., Inc. Coryneform bacteria deficient in a cell surface protein

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458759B1 (en) * 1996-04-26 2002-10-01 Ony, Inc. Compositions and methods for isolating lung surfactant hydrophobic proteins SP-B and SP-C
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
WO2000047623A1 (en) * 1999-02-12 2000-08-17 Chiesi Farmaceutici S.P.A. Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant
WO2000076535A1 (en) * 1999-06-11 2000-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
WO2001080633A2 (en) * 2000-04-26 2001-11-01 Children's Hospital Medical Center Surfactant protein d for the prevention and diagnosis of pulmonary emphysema

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AMIN R S ET AL: "Surfactant protein deficiency in familial interstitial lung disease.", THE JOURNAL OF PEDIATRICS. JUL 2001, vol. 139, no. 1, July 2001 (2001-07-01), pages 85 - 92, XP002394844, ISSN: 0022-3476 *
DAVIS A J ET AL: "Lung function in premature lambs and rabbits treated with a recombinant SP-C surfactant.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE FEB 1998, vol. 157, no. 2, February 1998 (1998-02-01), pages 553 - 559, XP002418346, ISSN: 1073-449X *
GLASSER S W ET AL: "Altered stability of pulmonary surfactant in SP-C-deficient mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 22 MAY 2001, vol. 98, no. 11, 22 May 2001 (2001-05-22), pages 6366 - 6371, XP002394842, ISSN: 0027-8424 *
GLASSER STEPHAN W ET AL: "Pneumonitis and emphysema in sp-C gene targeted mice.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 18 APR 2003, vol. 278, no. 16, 18 April 2003 (2003-04-18), pages 14291 - 14298, XP002394847, ISSN: 0021-9258 *
HAFNER D ET AL: "CYCLOOXYGENASE-INHIBITION ENHANCES THE EFFECTS OF RSP-C SURFACTANT THERAPY IN A RAT LAVAGE MODEL OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)", EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, JENA, DE, vol. 55, no. 1, July 2003 (2003-07-01), pages 59 - 68, XP009024125, ISSN: 0940-2993 *
IKEGAMI MACHIKO ET AL: "Deficiency of SP-B reveals protective role of SP-C during oxygen lung injury.", JOURNAL OF APPLIED PHYSIOLOGY (BETHESDA, MD. : 1985) FEB 2002, vol. 92, no. 2, February 2002 (2002-02-01), pages 519 - 526, XP002394843, ISSN: 8750-7587 *
NOGEE LAWRENCE M ET AL: "Mutations in the surfactant protein C gene associated with interstitial lung disease.", CHEST. MAR 2002, vol. 121, no. 3 Suppl, March 2002 (2002-03-01), pages 20S - 21S, XP009070987, ISSN: 0012-3692 *
SANFORD L P ET AL: "Influence of genetic background on knockout mouse phenotypes.", METHODS IN MOLECULAR BIOLOGY (CLIFTON, N.J.) 2001, vol. 158, 2001, pages 217 - 225, XP009071124, ISSN: 1064-3745 *
THOMAS ALAN Q ET AL: "Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 1 MAY 2002, vol. 165, no. 9, 1 May 2002 (2002-05-01), pages 1322 - 1328, XP002394845, ISSN: 1073-449X *

Also Published As

Publication number Publication date
CA2507613A1 (en) 2004-07-08
AU2003302740A1 (en) 2004-07-14
BR0317132A (en) 2005-10-25
EP1589980A2 (en) 2005-11-02
WO2004056310A2 (en) 2004-07-08
WO2004056310A3 (en) 2005-09-01
JP2006519588A (en) 2006-08-31
CN1731932A (en) 2006-02-08
CN100401896C (en) 2008-07-16

Similar Documents

Publication Publication Date Title
EP1565187A4 (en) CANCER TREATMENT METHODS AND RELATED METHODS
EP1390077A4 (en) TREATMENT AND DIAGNOSIS OF DISEASES ASSOCIATED WITH MACROPHAGES
EP1495321A4 (en) HUMAN METABOLISM MODELS AND ASSOCIATED METHODS
EP1411849A4 (en) APPARATUS AND METHODS FOR TREATING TISSUE
EP1885281A4 (en) STENTS USED IN THERAPEUTIC TREATMENTS THROUGH BODILY LIGHTS AND METHODS OF USE
EP1578364A4 (en) COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISEASES
EP1933873A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PATIENTS WITH POSITIVE DISEASES FOR SELF-ANTIBODIES
EP1503685A4 (en) APPARATUS AND METHOD FOR THERMO-IMPLANTABLE TREATMENT
EP1465854A4 (en) CHALCONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
DE50306850D1 (en) BENZODIAZEPINE-SUBSTITUTED PIPERDINES FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES
EP1555018A4 (en) TREATMENTS OF NEURODEGENERATIVE DISEASES
EP1796625A4 (en) NOVEL FENOFIBRATE FORMULATIONS AND METHODS OF TREATMENT RELATING THERETO
EP1773405A4 (en) METHOD OF DIAGNOSING, CONTROLLING AND TREATING PULMONARY DISEASES
IS7348A (en) N-pyrazinyl-phenylsulfonamide and their use in the treatment of cerebrovascular diseases
DE50200029D1 (en) Medical instrument for rinsing and / or suction
EP1539251A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DISEASES INVOLVING ANGIOGENESIS
ID27576A (en) USE OF CYCOSPORINE IN TREATMENT OF AUTOIMUN DISEASE DISEASES
EP1560572A4 (en) TOPICAL PEST FORMULATIONS AND METHODS OF TREATMENT
EP1589980A4 (en) DIAGNOSTIC AND TREATMENT METHODS FOR INTERSTITIAL PULMONARY DISEASES
EP1611120A4 (en) NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP1429775A4 (en) METHODS OF TREATING PULMONARY DISEASES
EP1692305A4 (en) DIAGNOSIS AND TREATMENT OF DISEASES CAUSED BY DEFECTS IN THE BOUTNEVILLE TUBEREUSE SCLEROSIS PATHWAY
ATE389742T1 (en) TISSUE TREATMENT PRODUCTS
EP1682171A4 (en) COMPOSITIONS AND METHODS FOR TREATING NERVOUS DISEASES
DE60315490D1 (en) THERAPEUTIC TREATMENT

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050609

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 61/00 20060101AFI20060404BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/00 20060101ALI20060828BHEP

Ipc: A01K 67/00 20060101ALI20060828BHEP

Ipc: G01N 33/00 20060101ALI20060828BHEP

Ipc: A61K 33/00 20060101ALI20060828BHEP

Ipc: A61K 31/00 20060101ALI20060828BHEP

Ipc: A01N 61/00 20060101AFI20060404BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070307

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/17 20060101ALI20070226BHEP

Ipc: C12N 15/00 20060101ALI20070226BHEP

Ipc: A01K 67/00 20060101ALI20070226BHEP

Ipc: G01N 33/00 20060101ALI20070226BHEP

Ipc: A61K 33/00 20060101ALI20070226BHEP

Ipc: A61K 31/00 20060101ALI20070226BHEP

Ipc: A01N 61/00 20060101AFI20060404BHEP

17Q First examination report despatched

Effective date: 20070615

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080701